Page 68 - GPD-3-3

Gene & Protein in Disease Amino acid metabolism in neurodegeneration

61. Salek RM, Xia J, Innes A, et al. A metabolomic study of the Mol Sci. 2019;20:728.
CRND8 transgenic mouse model of Alzheimer’s disease. doi: 10.3390/ijms20030728
Neurochem Int. 2010;56:937-947.
73. McCarty MF, Lerner A. Perspective: Low risk of Parkinson’s
doi: 10.1016/j.neuint.2010.04.001 disease in quasi-vegan cultures may reflect GCN2-mediated
62. Li H, Ye D, Xie W, et al. Defect of branched-chain upregulation of parkin. Adv Nutr. 2021;12:355-362.
amino acid metabolism promotes the development of doi: 10.1093/advances/nmaa112
Alzheimer’s disease by targeting the mTOR signaling. Biosci
Rep. 2018;38:BSR20180127. 74. Sbodio JI, Snyder SH, Paul BD. Transcriptional control of
amino acid homeostasis is disrupted in Huntington’s disease.
doi: 10.1042/BSR20180127 Proc Natl Acad Sci U S A. 2016;113:8843-8848.
63. Horgusluoglu E, Neff R, Song WM, et al. Integrative doi: 10.1073/pnas.1608264113
metabolomics-genomics approach reveals key metabolic
pathways and regulators of Alzheimer’s disease. Alzheimers 75. Gruber B, Kłaczkow G, Jaworska M, et al. Huntington’s
Dement. 2022;18:1260-1278. disease--imbalance of amino acid levels in plasma of
patients and mutation carriers. Ann Agric Environ Med.
doi: 10.1002/alz.12468 2013;20:779-783.
64. Bockaert J, Marin P. mTOR in brain physiology and 76. McGarry A, Gaughan J, Hackmyer C, et al. Cross-sectional
pathologies. Physiol Rev. 2015;95:1157-1187. analysis of plasma and CSF metabolomic markers in
doi: 10.1152/physrev.00038.2014 Huntington’s disease for participants of varying functional
disability: A pilot study. Sci Rep. 2020;10:20490.
65. Baik SH, Kang S, Lee W, et al. A breakdown in metabolic
reprogramming causes microglia dysfunction in Alzheimer’s doi: 10.1038/s41598-020-77526-9
disease. Cell Metab. 2019;30:493-507.e6. 77. Andersen JV, Skotte NH, Aldana BI, Nørremølle A,
doi: 10.1016/j.cmet.2019.06.005 Waagepetersen HS. Enhanced cerebral branched-
chain amino acid metabolism in R6/2 mouse model of
66. Devi L, Ohno M. Deletion of the eIF2α Kinase GCN2 fails Huntington’s disease. Cell Mol Life Sci. 2019;76:2449-2461.
to rescue the memory decline associated with Alzheimer’s
disease. PLoS One. 2013;8:e77335. doi: 10.1007/s00018-019-03051-2
doi: 10.1371/journal.pone.0077335 78. Paul BD. Cysteine metabolism and hydrogen sulfide
signaling in Huntington’s disease. Free Radic Biol Med.
67. Grallert B, Boye E. GCN2, an old dog with new tricks. 2022;186:93-98.
Biochem Soc Trans. 2013;41:1687-1691.
doi: 10.1016/j.freeradbiomed.2022.05.005
doi: 10.1042/BST20130210
79. Pryor WM, Biagioli M, Shahani N, et al. Huntingtin
68. Han W, Sapkota S, Camicioli R, Dixon RA, Li L. Profiling promotes mTORC1 signaling in the pathogenesis of
novel metabolic biomarkers for Parkinson’s disease using Huntington’s disease. Sci Signal. 2014;7:ra103.
in-depth metabolomic analysis. Mov Disord. 2017;32:
1720-1728. doi: 10.1126/scisignal.2005633
doi: 10.1002/mds.27173 80. Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR
induces autophagy and reduces toxicity of polyglutamine
69. Masato A, Plotegher N, Boassa D, Bubacco L. Impaired expansions in fly and mouse models of Huntington disease.
dopamine metabolism in Parkinson’s disease pathogenesis. Nat Genet. 2004;36:585-595.
Mol Neurodegener. 2019;14:35.
doi: 10.1038/ng1362
doi: 10.1186/s13024-019-0332-6
81. Bailus BJ, Scheeler SM, Simons J, et al. Modulating FKBP5/
70. Shao Y, Li T, Liu Z, et al. Comprehensive metabolic profiling FKBP51 and autophagy lowers HTT (huntingtin) levels.
of Parkinson’s disease by liquid chromatography-mass Autophagy. 2021;17(12):4119-4140.
spectrometry. Mol Neurodegener. 2021;16:4.
doi: 10.1080/15548627.2021.1904489
doi: 10.1186/s13024-021-00425-8
82. Patin F, Corcia P, Vourc’h P, et al. Omics to explore
71. Figura M, Kuśmierska K, Bucior E, et al. Serum amino amyotrophic lateral sclerosis evolution: The central role
acid profile in patients with Parkinson’s disease. PLoS One. of arginine and proline metabolism. Mol Neurobiol.
2018;13:e0191670. 2017;54:5361-5374.
doi: 10.1371/journal.pone.0191670 doi: 10.1007/s12035-016-0078-x
72. Zhu Z, Yang C, Iyaswamy A, et al. Balancing mTOR signaling 83. Ikenaka K, Atsuta N, Maeda Y, et al. Increase of arginine
and autophagy in the treatment of Parkinson’s disease. Int J dimethylation correlates with the progression and prognosis

Volume 3 Issue 3 (2024) 14 doi: 10.36922/gpd.3294